TY - JOUR
T1 - Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin
AU - Fuchs, Beth Burgwyn
AU - Rajamuthiah, Rajmohan
AU - Souza, Ana Carolina Remondi
AU - Eatemadpour, Soraya
AU - Rossoni, Rodnei Dennis
AU - Santos, Daniel Assis
AU - Junqueira, Juliana C.
AU - Rice, Louis B.
AU - Mylonakis, Eleftherios
N1 - Publisher Copyright:
© 2016 Future Science Ltd.
PY - 2016/2
Y1 - 2016/2
N2 - Background: We identified auranofin as an antimicrobial compound utilizing a high-throughput screen using a Caenorhabditis elegans-Staphylococcus aureus infection model. Results/methodology: Treatment of infected nematodes with auranofin resulted in a prolonged survival rate of 95%, reached with 0.78 μg/ml. Further investigation of the antimicrobial activity of auranofin found inhibition against S. aureus, Enterococcus faecium and Enterococcus faecalis. Importantly, the fungal pathogens Cryptococcus neoformans was also effectively inhibited with an MIC at 0.5 μg/ml. Auranofin appears to target the thioredoxin system. Conclusion: This work provides extensive additional data on the antibacterial effects of auranofin that includes both reference and clinical isolates and reports a novel inhibition of fungal pathogens by this compound.
AB - Background: We identified auranofin as an antimicrobial compound utilizing a high-throughput screen using a Caenorhabditis elegans-Staphylococcus aureus infection model. Results/methodology: Treatment of infected nematodes with auranofin resulted in a prolonged survival rate of 95%, reached with 0.78 μg/ml. Further investigation of the antimicrobial activity of auranofin found inhibition against S. aureus, Enterococcus faecium and Enterococcus faecalis. Importantly, the fungal pathogens Cryptococcus neoformans was also effectively inhibited with an MIC at 0.5 μg/ml. Auranofin appears to target the thioredoxin system. Conclusion: This work provides extensive additional data on the antibacterial effects of auranofin that includes both reference and clinical isolates and reports a novel inhibition of fungal pathogens by this compound.
KW - Bucillus subtilis
KW - Candida albicans
KW - Cryptococcus neoformans
KW - Enterococcus faecalis
KW - Enterococcus faecium
KW - Staphylococcus aureus
KW - antimicrobial
KW - auranofin
UR - http://www.scopus.com/inward/record.url?scp=84958050404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958050404&partnerID=8YFLogxK
U2 - 10.4155/fmc.15.182
DO - 10.4155/fmc.15.182
M3 - Article
C2 - 26808006
AN - SCOPUS:84958050404
SN - 1756-8919
VL - 8
SP - 117
EP - 132
JO - Future Medicinal Chemistry
JF - Future Medicinal Chemistry
IS - 2
ER -